These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 33152937)

  • 1. Therapeutic advances in Fabry disease: The future awaits.
    Kant S; Atta MG
    Biomed Pharmacother; 2020 Nov; 131():110779. PubMed ID: 33152937
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetics and Gene Therapy of Anderson-Fabry Disease.
    Simonetta I; Tuttolomondo A; Di Chiara T; Miceli S; Vogiatzis D; Corpora F; Pinto A
    Curr Gene Ther; 2018; 18(2):96-106. PubMed ID: 29618309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
    Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
    Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The treatment for Fabry disease: focus on agalsidase alpha and beta].
    Nisticò R; Pisani A
    Recenti Prog Med; 2021 Oct; 112(10):75e-84e. PubMed ID: 34647542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fabry disease.
    Tarabuso AL
    Skinmed; 2011; 9(3):173-7. PubMed ID: 21675497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA.
    Higuchi T; Shimada Y; Takahashi Y; Kato F; Ohashi T; Kobayashi H
    Mol Genet Metab; 2024; 143(1-2):108545. PubMed ID: 39068683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of fabry disease: current and emerging strategies.
    Rozenfeld P; Neumann PM
    Curr Pharm Biotechnol; 2011 Jun; 12(6):916-22. PubMed ID: 21235448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
    Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
    Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Fabry mice treated with recombinant adeno-associated virus 2/8-mediated gene transfer.
    Choi JO; Lee MH; Park HY; Jung SC
    J Biomed Sci; 2010 Apr; 17(1):26. PubMed ID: 20398385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alpha-galactosidase A-Tat fusion enhances storage reduction in hearts and kidneys of Fabry mice.
    Higuchi K; Yoshimitsu M; Fan X; Guo X; Rasaiah VI; Yen J; Tei C; Takenaka T; Medin JA
    Mol Med; 2010; 16(5-6):216-21. PubMed ID: 20454522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study.
    Hughes DA; Nicholls K; Shankar SP; Sunder-Plassmann G; Koeller D; Nedd K; Vockley G; Hamazaki T; Lachmann R; Ohashi T; Olivotto I; Sakai N; Deegan P; Dimmock D; Eyskens F; Germain DP; Goker-Alpan O; Hachulla E; Jovanovic A; Lourenco CM; Narita I; Thomas M; Wilcox WR; Bichet DG; Schiffmann R; Ludington E; Viereck C; Kirk J; Yu J; Johnson F; Boudes P; Benjamin ER; Lockhart DJ; Barlow C; Skuban N; Castelli JP; Barth J; Feldt-Rasmussen U
    J Med Genet; 2017 Apr; 54(4):288-296. PubMed ID: 27834756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term correction of globotriaosylceramide storage in Fabry mice by recombinant adeno-associated virus-mediated gene transfer.
    Park J; Murray GJ; Limaye A; Quirk JM; Gelderman MP; Brady RO; Qasba P
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3450-4. PubMed ID: 12624185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and Investigational Therapeutics for Fabry Disease.
    Felis A; Whitlow M; Kraus A; Warnock DG; Wallace E
    Kidney Int Rep; 2020 Apr; 5(4):407-413. PubMed ID: 32274449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucosylceramide synthase inhibition with lucerastat lowers globotriaosylceramide and lysosome staining in cultured fibroblasts from Fabry patients with different mutation types.
    Welford RWD; Mühlemann A; Garzotti M; Rickert V; Groenen PMA; Morand O; Üçeyler N; Probst MR
    Hum Mol Genet; 2018 Oct; 27(19):3392-3403. PubMed ID: 29982630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chaperone Therapy in Fabry Disease.
    Weidemann F; Jovanovic A; Herrmann K; Vardarli I
    Int J Mol Sci; 2022 Feb; 23(3):. PubMed ID: 35163813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human α-Galactosidase A Mutants: Priceless Tools to Develop Novel Therapies for Fabry Disease.
    Modrego A; Amaranto M; Godino A; Mendoza R; Barra JL; Corchero JL
    Int J Mol Sci; 2021 Jun; 22(12):. PubMed ID: 34204583
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An expert consensus document on the management of cardiovascular manifestations of Fabry disease.
    Linhart A; Germain DP; Olivotto I; Akhtar MM; Anastasakis A; Hughes D; Namdar M; Pieroni M; Hagège A; Cecchi F; Gimeno JR; Limongelli G; Elliott P
    Eur J Heart Fail; 2020 Jul; 22(7):1076-1096. PubMed ID: 32640076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutation-specific Fabry disease patient-derived cell model to evaluate the amenability to chaperone therapy.
    Lenders M; Stappers F; Niemietz C; Schmitz B; Boutin M; Ballmaier PJ; Zibert A; Schmidt H; Brand SM; Auray-Blais C; Brand E
    J Med Genet; 2019 Aug; 56(8):548-556. PubMed ID: 31010832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of Neutralizing Anti-drug Antibody Formation and Clinical Relevance on Therapeutic Efficacy of Enzyme Replacement Therapies in Fabry Disease.
    Lenders M; Brand E
    Drugs; 2021 Nov; 81(17):1969-1981. PubMed ID: 34748189
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.